NCT02429622View on ClinicalTrials.gov

Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions
Esophageal Neoplasms
Interventions
RADIATION

IMRT simultaneous integrated boost

To achieve a prophylactic dosage and radical dosage once respectively

DRUG

Paclitaxel

Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

DRUG

Nedaplatin

Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

PROCEDURE

Esophagectomy

Radical esophagectomy 4-6 weeks after neoadjuvant therapy

Trial Locations (1)

100021

Zefen Xiao, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT02429622 - Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma | Biotech Hunter | Biotech Hunter